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Abstract
Several ethical aspects in the management of Autosomal Dominant Polycystic Kidney Dis-
ease (ADPKD) are still controversial, including family planning and testing for disease pres-
ence in at-risk individuals. We performed an online survey aiming to assess the opinion and
current clinical practice of European pediatric and adult nephrologists, as well as geneticists.
A total of 410 clinicians (53% male, mean (SD) age of 48 (10) years) responded, including
216 pediatric nephrologists, 151 adult nephrologists, and 43 clinical geneticists. While the 3
groups agreed to encourage clinical testing in asymptomatic ADPKD minors and adults,
only geneticists would recommend genetic testing in asymptomatic at-risk adults (P<0.001).
Statistically significant disagreement between disciplines was observed regarding the ethi-
cal justification of prenatal genetic diagnosis, termination of pregnancy and pre-implantation
genetic diagnosis (PGD) for ADPKD. Particularly, PGD is ethically justified according to
geneticists (4.48 (1.63)), whereas pediatric (3.08 (1.78); P<0.001) and adult nephrologists
(3.66 (1.88); P<0.05) appeared to be less convinced. Our survey suggests that most clini-
cians support clinical testing of at-risk minors and adults in ADPKD families. However, there
is no agreement for genetic testing in asymptomatic offspring and for family planning, includ-
ing PGD. The present data highlight the need for a consensus among clinicians, to avoid
that ADPKD families are being given conflicting information.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kid-
ney disease [1, 2]. In the absence of a cure, half of the patients currently develop end stage
renal disease (ESRD) in their fifth or sixth decade, requiring renal replacement therapy [3].
Since most patients remain a- or oligo-symptomatic until adulthood, ADPKD is usually
regarded as a late-onset disease [4]. However, evidence is cumulating that renal injury starts
early in life, with the formation of renal cysts in utero [5]. Moreover, 2–5% of ADPKD patients
present in childhood with a broad phenotypic spectrum, ranging from a severe neonatal pre-
sentation [6] to the incidental finding of renal cysts detected on ultrasound [7]. Children diag-
nosed with ADPKD have proteinuria in up to 35% of cases, hypertension before a renal
function decline in up to 44% and more than half have urinary concentrating defects [4]. Sig-
nificant irreversible destruction of renal parenchyma will occur long before clinical symptoms
develop or a loss in glomerular filtration rate (GFR) is noted, due to hyperfiltration and hyper-
trophy of residual nephrons [8].
Whether asymptomatic at-risk individuals should be tested for the presence of the disease is
still a matter of controversy [9]. On the one hand, the absence of an effective cure [3], the
potential psychological stress related to the diagnosis of a chronic progressive disease in the
context of affected family members, possibly causing survival guilt or even ostracism [10, 11],
and potential financial and legal implications such as the inability to obtain life or medical
insurances [12] have been put forward against pre-symptomatic testing. On the other hand,
presymptomatic testing has prognostic implications (PKD1 versus PKD2) and may induce
early targeting of modifiable risk factors for disease progression [13], including hypertension
[14–16], proteinuria, urological complications [17] and hypercholesterolemia [18], increasing
the effectiveness of interventions to improve long-term renal survival [19]. This is indirectly
supported by the evidence of slower cyst growth in number and size in normotensive com-
pared to hypertensive children with ADPKD [20]. Effective blood pressure control from child-
hood on may also improve cardiovascular outcomes in this patient group, at high risk for early
cardiovascular events [21, 22]. A benefit accruing to all tested individuals, is the potential for
increased control over their own health and life, among other things informed reproductive
decision making [11].
ADPKD is most commonly diagnosed based on the family history and sonographic [23, 24]
or magnetic resonance imaging (MRI) findings [25]. However, for individuals younger than
15 years, uniform imaging diagnostic criteria are lacking [26],[27]. Moreover, definite exclu-
sion of ADPKD based on imaging is only possible in at-risk individuals aged 30–40 years or
older [23–25]. A definite diagnosis based on gene sequencing is not yet routinely used in clini-
cal practice given the presence of six PKD1 pseudogenes and tremendous allelic heterogeneity,
making molecular genetic testing challenging and expensive. While the diagnostic accuracy of
PKD1 and PKD2 gene screening was found to be lower than the accuracy of ultrasound exami-
nation in adults beyond the age of 30 years, the relative accuracy of genetic vs. ultrasound
screening was similar for children younger than 15 years in PKD1 and superior in PKD2 indi-
viduals [23]. A third diagnostic option is regular monitoring for disease manifestations such as
hypertension and proteinuria [4].
The advent of genetic testing for ADPKD [28] and advanced obstetric techniques in assisted
reproduction have given rise to new possibilities for prenatal diagnosis [29, 30] and potentially,
termination of pregnancy, and for pre-implantation genetic diagnosis (PGD) [31]. However,
the availability and financial coverage of these techniques varies from country to country [19].
Moreover, although evolving, the European legal landscape regarding practices in genetics,
PGD, and the governmental policies on the use of genetic information in insurance and
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employment is still very heterogeneous. Some countries have comprehensive provisions per-
taining to genetic testing in their biomedical and bioethical regulation (Norway [32], Spain
[33] and France [34]), while others have enacted laws specific to genetics [35] (Austria [36],
Germany [37], Hungary [38], Portugal [39], Sweden [40] and Switzerland [35]) or address
genetics within more general laws on health care issues (Czech Republic [41], Ireland [42] and
Lithuania [43]). In countries where genetic testing is not regulated by specific laws or provi-
sions, regulation related to patient rights and health care professionals’ duties is applied [44],
e.g. in Belgium [45]. The same applies to assisted reproduction: according to Turillazzi et al.
and Harper et al., PGD is outright banned in Austria and Switzerland, while laws in Germany,
Ireland and Italy leave some room for interpretation. PGD is allowed in Belgium, Bulgaria,
Cyprus, Czech Republic, Denmark, Finland, France, Greece, Latvia, Portugal, Romania, Spain,
Sweden and UK [46]; although the allowed indications for PGD vary by country to a major
extent [47].
Widely varying opinions towards presymptomatic predictive testing, genetic counseling
and family planning for ADPKD have been voiced by patients [48–50]. However, the attitudes
of clinicians and the underlying arguments towards these topics have never been studied; only
the opinion of nephrologists on screening modalities for unruptured intracranial aneurysms
in ADPKD has been published recently [51].
Therefore, the aim of this study was to gather representative information on these ethical
issues, from European pediatric and adult nephrologists and clinical geneticists.
Subjects and methods
Procedure
An online questionnaire was designed by 7 experts in the field of ADPKD, including 2 pediatric
and 3 adult nephrologists, as well as 2 clinical geneticists. The design was then validated and
approved by a group of 8 other ADPKD experts (3 pediatric, 3 adult nephrologists and 2 geneti-
cists). After approval by the Ethics Committee of Leuven University, the project was approved
and endorsed by the Working Group for Inherited Kidney Disorders of the European Society of
Pediatric Nephrology. To avoid sample bias, we chose to contact pediatric nephrologists and
geneticists throughout Europe. As this approach was not feasible for adult nephrologists, we
mainly focused on Germany and Belgium as two exemplary European countries differing in
legislation regarding genetic testing, as this might affect the clinicians’ clinical practice and opin-
ions. Belgium has no specific legislation on genetic testing [35], while Germany has an elaborated
and specific legal framework [52]. PGD has only become legal in Germany in December 2011
and is restricted to cases where the parents have a predisposition to a serious genetic illness [53],
as an exception to the Embryo Protection Act which banned PGD in 1990 [54].
To contact adult nephrologists, we used the national mailing lists from Belgium and Ger-
many. Pediatric nephrologists were contacted via the ESPN membership mailing list, consist-
ing of 1938 recipients, including fellows and non-European members. Geneticists were
recruited via the Facebook and Twitter groups of the European Society for Human Genetics
and via a mailing list, obtained as previously described [55]. Two reminders were sent out at
2-week intervals. No monetary or other incentive was offered to the caregivers. We complied
with the terms of service for the website from which we collected the data for analysis.
Questionnaire
A 17-item questionnaire was developed for pediatric and adult nephrologists, and an adapted
15-item questionnaire for geneticists. The survey instruments (Supporting information S1 and
S2 Appendices) included 3 sections.
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First, sociodemographic factors including gender, age, country, and practice/center charac-
teristics were collected. Countries were divided in 4 groups based on geographical regions
described by the United Nations [56].
Second, multiple-choice questions aimed at defining the clinicians’ current clinical practice.
We assessed (i) whom the respondents consider responsible for informing the minor about
his/her genetic risk, (ii) which methods they apply for testing asymptomatic at-risk individuals,
and (iii) whether they inform their patients about the possibilities of prenatal diagnostics and
PGD. Next, their recommendation was asked for the management of a fictitious case: “a
35-year-old ADPKD patient with an asymptomatic child of 6 years, and several affected family
members are known with early disease manifestation”.
Third, a series of statements were used to establish the clinicians’ opinions and beliefs
regarding clinical and ethical issues such as predictive (genetic) testing in at-risk individuals,
prenatal genetic diagnosis by means of chorionic villus sampling or amniocentesis, termina-
tion of pregnancy and PGD for ADPKD. We used a 6-point Likert response scale, in which a
score of 1 means the respondent strongly disagrees, and a score of 6 means a strong agreement
on a given statement. In the Results section answers are shown as the mean of the numerical
mean score and standard deviation (SD). At-risk individuals were defined as first-degree rela-
tives of individuals diagnosed or suspected to have ADPKD. Testing for ADPKD comorbidi-
ties such as hypertension and proteinuria was considered as clinical testing.
Statistical analysis
Statistical analyses were performed using Stata 14/SE. Given that individual survey questions
collected data in a variety of ways (e.g., dichotomous nominal, multi-level nominal and ordi-
nal, and six-point Likert scales), different types of analysis were performed to assess various
questions. Relationships between categorical responses were assessed using Chi-square. Six-
point Likert data measuring agreement with prompts were treated as numeric allowing t-tests
to be utilized for group comparisons. For all analyses a 0.05 significance level was used for
establishing statistical significance. However, the Bonferroni correction was employed to con-
trol for type I error inflation through multiple comparisons. Missing data were handled
through list-wise deletion for each specific test. Dichotomous responses on who is responsible
for informing at-risk individuals were recoded into a five-point ordinal scale (only parents,
mainly parents, parents & professionals, mainly professionals, only professionals). These data
were utilized to generate figures for graphical analysis only. For the current approach on
informing on both prenatal genetic diagnosis and PGD, logistic regression analysis was per-
formed to detect the possible influence of gender, work setting, ADPKD research involvement,
the availability to genetic testing and/or counseling and possible reasons not to test their
patients for disease presence such as inducing stress, financial implications, the absence of a
curative treatment.
Finally, to determine the impact of legislative differences in Germany, Ordinary Least
Squares (OLS) regression models were estimated using the six-point Likert items indicating
agreement as dependent variables. Models were verified through Independent and Identically
Distributed (IID) testing, which indicated no model bias due to the nature of the dependent
variables.
Results
Study population
A total of 410 physicians completed the online survey. For pediatric nephrologists, 686 out of
1938 recipients (35.4%) opened the mail, of whom 216 (31.5%) responded on the questionnaire.
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Their characteristics are given in Table 1. Most of the respondents work in an academic set-
ting and one third was or is involved in patient-oriented ADPKD research in the past or at
present.
Current clinical practice
All respondents agreed that the task of informing an at-risk minor about his or her genetic risk
for ADPKD at adult age should be a shared responsibility of the professional care givers and
the parents (Fig 1).
Considering the diagnostic methods applied to test for the presence of ADPKD in asymp-
tomatic at-risk individuals, ultrasound, blood pressure measurement and urinalysis are rou-
tinely used by 50–60% of both adult and pediatric nephrologists (Fig 2). GFR is estimated by
Table 1. Demographic characteristics of respondents.
Total Sample
(N = 410)
Adult nephrologists
(N = 151)
Pediatric nephrologists
(N = 216)
Geneticists
(N = 43)
Male 53.4% 65.6% 43.1% 62.8%
Mean age (SD) 48.3 (9.8) 46.9 (10.2) 48.3 (9.3) 52.8 (9.9)
Country
1. Western Europe 55.4% 90.1% 34.7% 37.2%
 Belgium 28.1% 60.9% 8.8% 9.3%
Germany 15.4% 23.2% 10.2% 14.0%
2. Eastern Europe 6.6% 2.0% 8.3% 14.0%
3. Northern Europe 12.4% 0.7% 17.6% 27.9%
4. Southern Europe 16.3% 6.6% 22.2% 20.9%
5. Others 9.3% 0.7% 17.1% 0.0%
Academic work setting 70.5% 42.4% 86.6% 88.4%
Involved in ADPKD research 32.9% 31.8% 33.8% 32.6%
Access to genetic testing for ADPKD 56.8% 49.7% 58.3% 74.4%
Access to genetic counseling for ADPKD
patients
79.8% 70.2% 82.4% 100%
https://doi.org/10.1371/journal.pone.0185779.t001
Fig 1. Responsibility of informing at-risk individuals about their genetic risk. Dot, triangles and square
represent mean per group, lines ± 1 SD.
https://doi.org/10.1371/journal.pone.0185779.g001
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50% of adult but only 35% of pediatric nephrologists. Most adult and pediatric nephrologists
use rarely MRI, computed tomography (CT) and genetic screening, unless in selected patients.
The attitude towards informing ADPKD patients about the possibility of prenatal genetic
diagnosis by means of chorionic villus sampling or amniocentesis, in case of future pregnan-
cies, differed distinctly between the disciplines (P<0.001). Two thirds of geneticists actively
inform the families, the other third does this upon patient request. In contrast, only a minority
of adult and pediatric nephrologists routinely informs their patients (Fig 3A). Likewise, geneti-
cists almost unanimously inform their patients about the possibility of in vitro fertilization
with PGD either routinely (63%) or upon request (30%), whereas only 41% of adult and 23%
of pediatric nephrologists inform their patients about this option (P<0.001) (Fig 3B). The dif-
ferences in counseling attitude were not attributable to any factors other than the professional
discipline.
Current clinical practices were evaluated based on a fictitious clinical case of an asymptom-
atic child with a family history of ADPKD. Of the 410 respondents, an annual blood pressure
measurement and urine checkup was recommended by 251 respondents (61.2%). Eighty
(19.5%) recommended genetic testing for both parent and child and 73 (17.8%) recommended
clinical and/or genetic testing only when the child would have reached adult age. Hundred
fifty two (37.1%) respondents advised against investigations in childhood. Of these, 24 (15.8%)
argued that the disease does not manifest before adulthood, 47 (30.9%) justified postponing
diagnostic evaluation by the risk of inducing psychological stress, 41 (27%) cited the current
unavailability of an efficacious treatment, 33 (21.7%) potential insurance problems, and 7
Fig 2. Use of different diagnostic techniques to test for ADPKD in at-risk adults and minors. Abbreviations: BP: blood pressure, eGFR:
estimated glomerular filtration rate, U: urine analysis, US: ultrasound, MRI/CT: magnetic resonance imaging / computed tomography, Genetic:
genetic testing, None: none of the previously mentioned techniques.
https://doi.org/10.1371/journal.pone.0185779.g002
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(4.6%) reasoned that no definite diagnostic method exists at childhood age. Geneticists were
significantly more likely to recommend genetic testing at adult age than nephrologists
(P<0.001).
Views on controversies and ethical issues
Clinical and predictive genetic testing in at-risk individuals. The three groups of clini-
cians similarly supported clinical testing in at-risk adults (full sample mean (SD): 5.31 (1.16)
points on a 6-point scale) (Fig 4). Older clinicians were less likely to agree on this (P<0.05).
While all groups encouraged clinical testing in at-risk minors (full sample mean (SD): 4.76
(1.50)), pediatric nephrologists showed significantly stronger support for seeking a diagnosis
on a clinical basis in children at-risk compared to geneticists (P<0.001). In the multivariate
analysis, adult nephrologists working in an academic setting were more supportive of clinical
testing of minors (P<0.01). Those unwilling to test for the presence of the disease because of
the perceived absence of curative treatment options or because they considered the disease as
manifesting only in adulthood, were less likely to agree with clinical testing of minors (P<0.05
and P<0.01, respectively).
All groups moderately disagreed on performing genetic testing in at-risk minors (full sam-
ple mean (SD): 2.53 (1.57)). Genetic testing in at-risk adults was favored by geneticists but not
by the nephrologist groups (P<0.001). Clinicians working in Germany were less in favor of
genetic testing compared to clinicians working elsewhere: mean (SD) for at-risk minors was
1.83 (1.49) for clinicians working in Germany. For clinicians elsewhere, this was 2.30 (1.71)
(P<0.01). For at-risk adults, mean (SD) was 2.27 (1.63) for clinicians working in Germany
compared to 2.65 (1.84) for clinicians working elsewhere (P<0.05).
Family planning in ADPKD. The respondents tended to disagree with the statement that
prenatal genetic diagnostics, by means of chorionic villus sampling or amniocentesis, is ethi-
cally justified (full sample mean (SD): 3.08 (1.76)) (Fig 5). Moreover, adult nephrologists work-
ing in an academic setting, and German respondents were more likely to disagree (P<0.01 and
Fig 3. Current practice on informing the patient about the possibility of (a) prenatal genetic diagnosis by
chorionic villus sampling or amniocentesis and (b) pre-implantation genetic diagnosis (PGD) for ADPKD.
https://doi.org/10.1371/journal.pone.0185779.g003
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P<0.001, respectively). However, geneticists exhibited a more positive view on prenatal genetic
testing compared to pediatric nephrologists (P<0.01) and adult nephrologists (P<0.05).
The respondents also disagreed with the statement that termination of pregnancy for
fetuses diagnosed with ADPKD is ethically justified (full sample mean (SD): 2.78 (1.67)).
However, geneticists had a more liberal view on this issue than pediatric (P<0.001) and adult
nephrologists (P<0.01).
Fig 4. (Dis)agreement on proposing clinical and genetic testing in at-risk minors and adults. Scoring ranged from
1 = strongly disagree to 6 = strongly agree. Dots, triangles and squares represent mean per group, lines the 95% confidence
interval. **: P<0.01, ***: P<0.001, for difference between geneticists and combined nephrologist groups.
https://doi.org/10.1371/journal.pone.0185779.g004
Fig 5. (Dis)agreement on ethical justification of prenatal diagnostics, termination of pregnancy and preimplantation
genetic diagnostics (PGD) in pregnant women with ADPKD. Scoring ranged from 1 = strongly disagree to 6 = strongly agree.
Dots, triangles and squares represent mean per group, lines the 95% confidence interval. **: P<0.01, ***: P<0.001, for difference
between geneticists and combined nephrologist groups.
https://doi.org/10.1371/journal.pone.0185779.g005
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Geneticists strongly felt that PGD is ethically justified if a parent-to-be suffers from
ADPKD (4.48 (1.63)), whereas pediatric (P<0.001) and adult nephrologists (P<0.05) had a
rather neutral view on this new technology.
Academic adult nephrologists and respondents from Germany were less likely to agree with
either termination of pregnancy or PGD (P<0.001 for both).
Discussion
This study provides an assessment of ethical views and management attitudes among Euro-
pean healthcare professionals towards ADPKD. To date, only three reports on ethical issues in
ADPKD have been published, focusing on patients’ opinions [48–50]. Two of them were per-
formed in the nineties [48, 50]. It is important to emphasize that this survey was performed
prior to the publication of the recent Kidney Disease: Improving Global Outcomes (KDIGO)
consensus, the first initiative to provide clinical practice guidelines on the management of
ADPKD [19], the European ADPKD Forum (EAF) Report [57] and prior to the approval of
tolvaptan use by the European Medicines Agency (EMA) [58].
The respondents broadly agreed that both minors and adults at-risk for ADPKD should be
tested for the presence of ADPKD. Notably, the support for clinical testing of minors was the
strongest among pediatric nephrologists, in keeping with their professional focus and greater
exposure to patients with early-onset symptomatic disease [4]. KDIGO participants reached
consensus that presymptomatic testing is not recommended for at-risk minors, but solely for
at-risk adults, by means of ultrasound or MRI. However, the report suggests at-risk children to
be screened for hypertension from the age of 5, with intervals of 3 years if screening is negative
[19]. The latter is in line with our observation that all disciplines encouraged clinical testing
for at-risk minors.
The most common arguments raised against testing of at-risk minors in this study were the
induction of psychological stress and the absence of a treatment–at that time—for the disease.
At least the latter notion requires re-consideration in the light of the approval of the use of tol-
vaptan for ADPKD by the EMA and its current use in selected adult patients [58].
The current prioritization of diagnostic measures in ADPKD screening was similar for
adults and minors, with ultrasound, blood pressure monitoring and urine analysis being the
preferred tools by the majority of respondents. Most adult and pediatric nephrologists appear
to choose MRI, CT and genetic testing only in selected cases. While MRI has a higher sensitiv-
ity in detecting small renal cysts in comparison with sonography [59], its use is still limited by
higher cost and the need for sedation in young children. The respondents clearly exhibited a
cautionary position towards predictive genetic testing in asymptomatic at-risk individuals,
except for geneticists who favored genetic testing in at-risk adults. In line with this clinical
practice, the KDIGO report considered molecular testing only to be required in case of atypical
renal imaging findings or clinical course, sporadic cases and reproductive counseling. It
remains to be seen whether the massive reduction of cost and time by the recent introduction
of next generation panel sequencing in routine genetic diagnostics will change the role of
genetic screening in ADPKD testing [28, 60].
We noticed large inter- and intra-discipline variety regarding the perceived appropriateness
of prenatal genetic diagnosis and termination of pregnancy, or PGD and the routine practice
of transmitting the respective information to ADPKD families.
Adult and pediatric nephrologists expressed cautious views on prenatal testing, mostly
rejected pregnancy termination and had a neutral attitude regarding PGD, whereas geneticists
felt more positively about prenatal genetic testing and potential pregnancy termination and
viewed PGD as clearly justified. In keeping with their ethical concerns, only 20–40% of
Clinicians’ opinion on ethical controversies in ADPKD
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nephrologists reported proactively informing all their patients about the available prenatal
and pre-implantation diagnostic options. This behavior contrasts the KDIGO consensus state-
ment that all ADPKD patients should have reproductive counseling and that PGD should be
included in this discussion [19]. In this context, a recent report clearly supports the importance
of discussing these issues with the patients and their families [49]. Two thirds of ADPKD
patients stated that PGD should be made available to prospective parents with this disease.
Moreover, 17% of patients not in ESRD and 18% of patients in ESRD would consider prenatal
diagnosis and termination of pregnancy; 50% of non-ESRD and 63% of ESRD patients
expressed an intention or wish to access PGD for themselves.
An important observation was that physicians working in Germany, consistently had more
negative attitudes regarding the ethical acceptability of predictive genetic testing in at-risk
individuals, prenatal genetic diagnostics, termination of pregnancy and PGD than physicians
from other countries. We hypothesize that this divergent behavior is due to the difference in
legislation between Germany and other European countries.
Our study has some limitations. First, we were unable to calculate the exact response rate
for adult nephrologists and geneticists as we used several channels to reach the maximum
number of people possible. Second, the optimal manner to explore underlying explanations
for attitudes regarding these ethical topics would be to perform a live or telephone open-ended
question survey. As this was not feasible, we opted for an online closed-ended survey. Of
important note, our questionnaire was first designed and then independently validated by
experts in the field of ADPKD, including 5 pediatric nephrologists, 6 adult nephrologists and 4
clinical geneticists in toto. Still, a selection bias could not be excluded as our questionnaire was
only accessible online and in English. Unanswered questions were dealt with through list-wise
deletion on a test by test basis.
We conclude that the heterogeneous attitudes observed in this survey within and across dis-
ciplines may cause transmission of conflicting information to patients by different clinicians.
Establishing a broad intra- and interdisciplinary consensus—if possible as these are sensitive
ethical issues—centered around patients’ needs is urgently required. Based on our results, there
is a clear need for standardization of care for ADPKD families. We propose to invoke a consen-
sus finding process of multidisciplinary teams at least per center and if possible at a national
level. In this process, not only treatment options and extrarenal complications but also practical
implications such as potential impact on work, insurance, lifestyle, family planning, and psycho-
logical health should be reflected. Once a consensus is reached and implemented as a guideline
to clinical practice, patients will no longer receive conflicting information. Importantly, family
planning counseling should be made available to all ADPKD patients at initial diagnosis, includ-
ing genetic counseling and informing them about the possibility of PGD, as suggested by the
EAF 2015 Report [5] and the KDIGO consensus [6]. Moreover, affected parents should be
informed about screening options for at-risk children. The ultimate goal is to make patients feel
sufficiently informed and empowered to make their own decisions. Checklists for both patients
and doctors, for initial diagnostics and follow-up care, as suggested by the KDIGO, could facili-
tate the provision of standardized care.
As a future perspective, it would be interesting to repeat this questionnaire in several years
to evaluate the impact of the KDIGO consensus statement and the availability of tolvaptan and
other upcoming treatment options on caregivers’ attitudes. Moreover, a comparison of care-
giver and patient opinions, surveyed simultaneously in the same geographic area, might reveal
important concerns, given the divergence between caregivers’ views compiled in this study
and published patient views [47–49].
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